Open AccessIntravenous immunoglobulins (IVIg) in the treatment of autoimmune diseases
Author(s) -
KAVERI S.V.,
DIETRICH G.,
HUREZ V.,
KAZATCHKINE M. D
Publication year - 1991
Publication title -
clinical & experimental immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 135
eISSN - 1365-2249
pISSN - 0009-9104
DOI - 10.1111/j.1365-2249.1991.tb05794.x
Subject(s) - immunology , medicine , antibody , intravenous immunoglobulins , autoimmune disease
SUMMARY Intravenous immunoglobulin (IVIg) therapy is increasingly used in autoimmune diseases. Although its efficacy has only been established in a few specific antibody‐mediated autoimmune conditions, accumulating evidence on the regulatory role of circulating immunoglobulins in the selection of peripheral B cell repertoires makes it an attractive potential therapeutic option to clinical immunologists. This overview briefiy discusses the current use of IVIg in human autoimmune diseases with a particular emphasis on the possible mechanisms by which IVIg could suppress pathological autoimmune responses.